articleEuropean Journal of CancerApr 19, 2006Closed access

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

MDMaria Dêbiec‐RychterRSRaf SciotALAxel Le CesneMSM. SchlemmerPHPeter Hohenberger

KU Leuven · Institut Gustave Roussy · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

898
total citations
FWCI
37.35
Percentile
100%
References
25
Citations per year

Authors

15

Topics & keywords

Topics
Keywords
  • PDGFRA
  • Imatinib
  • Internal medicine
  • Medicine
  • Imatinib mesylate
  • Exon
  • Oncology
  • GiST
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding